Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  CARDIOVASCULAR DISEASE DIAGNOSTICS
A Global Strategic Business Report

This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in Millions of US$. The major product segments analyzed are In Vitro Diagnostics, and In Vivo Diagnostics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 72 companies including many key and niche players worldwide such as Abbott Diagnostics, Biosite, Inc., Cambridge Heart, Inc., Cholestech Corp., Dade Behring, Inc., EP Medsystems, GE HealthCare, Liposcience, Inc., Philips Medical Systems, Roche Diagnostics, and Siemens Medical Solutions. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1096  PAGES:    415
PRICE:    $3950  DATE:       March 2008
COMPANIES:  72  MARKET DATA TABLES:   175
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  CARDIOVASCULAR DISEASE DIAGNOSTICS (Complete Report) Pages : 415   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
II. EXECUTIVE SUMMARY72$2250
  1. Industry Overview.....II-17 $700  
   Market Analysis.....II-1
Analysis by Product Type.....II-1
Cardiology Diagnostic Imaging: Future Outlook.....II-1
1$100
   Heart -Facts and Figures.....II-2
Swift Growth in Cardiovascular Disease Devices Market.....II-2
1$100
   Cardiovascular Diseases Damaging Human Health.....II-3
Mounting Healthcare Costs- “A Real Concern for Economies”.....II-3
Competition in the Cardiac Diagnostics Market.....II-3
Market Trends.....II-3
Advancement of POC Testing Propels Cardiovascular Diagnostics Market.....II-3
1$100
   Demand on Rise for POC Cardiac Markers.....II-4
Minimal Invasive Procedure Hogs the Limelight of Cardiovascular Treatment.....II-4
Advancements in Alternate-Site Coagulation Monitoring.....II-4
1$100
   Novel Imaging Techniques Boost In vivo Diagnostic Market.....II-5
Strong Demand for Risk Assessment Markers.....II-5
New Technologies Bring Diagnostics Closer to Patients.....II-5
1$100
   Trends Cited in the Imaging Technologies Market.....II-6
CT Scanners.....II-6
1$100
   MRI.....II-7
Move Towards Efficient Patient Data Management.....II-7
1$100
  2. CVD - Cause and Risk Factors.....II-86 $600  
   CVD - Global Facts.....II-8
Atherosclerosis - Leading Cause for CVD.....II-8
Risk Factors.....II-8
Irreversible Risk Factors.....II-8
Increasing age.....II-8
1$100
   Sex (gender).....II-9
Heredity (including Race).....II-9
Risk Factors that can be controlled.....II-9
Tobacco Smoke.....II-9
High Blood Cholesterol.....II-9
LDL Cholesterol.....II-9
1$100
   HDL Cholesterol.....II-10
Triglyceride levels.....II-10
1$100
   Hypercholesterolemia - Conditions Associated with Cholesterol Level.....II-11
High Blood Pressure.....II-11
BP - Leading Cause of Cardiovascular Disease in Young Adults.....II-11
Physical Inactivity.....II-11
1$100
   Obesity and Overweight.....II-12
Diabetes Mellitus.....II-12
Cardiovascular Disease and Homocysteine Levels.....II-12
1$100
   Measures for Reducing Cardiovascular Diseases.....II-13
1$100
  3. Cardiovascular Disease and Conditions.....II-142 $200  
   Angina Pectoris.....II-14
Arrhythmias.....II-14
Sudden Cardiac Death (SCD).....II-14
Stroke.....II-14
1$100
   Congestive Heart Failure.....II-15
Cardiovascular Disease Involving Transplant Patients.....II-15
1$100
  4. Diagnostic Tests for Cardiovascular Diseases.....II-1612 $900  
   In-Vitro Cardiovascular Diagnostics.....II-16
Cholesterol Testing.....II-16
Use of Markers.....II-16
Creatine Kinase MB.....II-16
1$100
   Troponin T and Troponin I.....II-17
C-reactive Protein.....II-17
Plasminogen Activator Inhibitor-1.....II-17
1$100
   D-Dimer.....II-18
Thrombus Precursor Protein.....II-18
Other Cardiac Markers.....II-18
Demand Grows for Risk Assessment Markers.....II-18
A Step Forward in Cardiovascular Risk Assessment.....II-18
1$100
   In Vivo Diagnostic Tests.....II-19
Computer Imaging / Tomography.....II-19
Electron Beam Computer Tomography (EBCT).....II-19
Appropriate Conditions for EBCT Diagnosis.....II-19
1$100
   Cardiac Positron Emission Tomography (PET).....II-20
Digital Cardiac Angiography/ Digital Subtraction Angiography.....II-20
Magnetic Resonance Imaging (MRI).....II-20
1$100
   Single Photon Emission Computed Tomography (SPECT).....II-21
Echocardiography.....II-21
1$100
   Different Types of Echo-techniques.....II-22
M-mode (Motion mode, One-dimensional).....II-22
Two-Dimensional (Cross-sectional).....II-22
Stress Echocardiogram (Stress Echo).....II-22
Transesophageal Echocardiogram (TEE).....II-22
1$100
   Risks.....II-23
Ultrasound Tests.....II-23
Doppler Ultrasound.....II-23
Intravascular Ultrasound.....II-23
Working.....II-23
1$100
   Comparative Facts Related to Definitive Diagnosis of Cardiovascular Disease.....II-24
Nuclear Cardiology Tests.....II-24
1$100
   Applications.....II-25
Types of Nuclear Cardiology Tests.....II-25
Myocardial Perfusion Imaging.....II-25
Applications.....II-25
Risks.....II-25
1$100
   Ventricular Function Test.....II-26
Types:.....II-26
Testing Cardiac Stress.....II-26
Cardio Vascular Disease Diagnostics Tests in the Pipeline.....II-26
Aderis MRE-0470.....II-26
CardioMEMS Novel Technology.....II-26
1$100
   Technology Platform.....II-27
1$100
  5. Product Launches and Developments.....II-2817 $900  
   Philips Rolls Out 256-slice CT scanner, Brilliance iCT Scanner.....II-28
Royal Philips Launches Live 3D Transesophageal Echocardiogram Probe.....II-28
GE Healthcare Launches Vivid e Ultrasound Systems.....II-28
Cardionetics Launches ECG Monitor for 24-Hour Real-Time Cardiac Diagnosis.....II-28
Siemens Launches Imaging Release for the ACUSON Sequoia Platform.....II-28
1$100
   GE Healthcare Launches Version 2.0 of Centricity Cardiology CA1000.....II-29
GE Healthcare Introduces New Capabilities to CardioSoft Diagnostic Software.....II-29
GE Healthcare’s Lightspeed VCT Offers Imaging at 70% Lower Exposure.....II-29
Roche Diagnostics Launches cobas h 232 Portable Cardiac Marker System (Outside
  US).....II-29
1$100
   Royal Philips Launches New Imaging Tool for Complex Cardiac Arrhythmias.....II-30
Siemens Medical Introduces syngo® US, New Echocardiography Solution......II-30
Dade Behring Introduces CardioPhase® hsCRP Test for Multiple Testing
  Platforms......II-30
Shimadzu Launches Two Models in Angiographic Imaging.....II-30
1$100
   Omron Healthcare Introduces Non Invasive Vascular Profiling System.....II-31
Abbott Launches XIENCE V, New Coronary Stent System.....II-31
Siemens Medical Introduces Acuson AcuNav 8F, an Advanced Ultrasound Catheter .....II-31
BioMérieux Introduces High Performance VIDAS Troponin I Ultra.....II-31
1$100
   Siemens Launches Acuson X300 Ultrasound Platform.....II-32
Siemens Releases Web-Enabled CT.....II-32
GE Introduces Latest Electrocardiograph Device, MAC 3500.....II-32
1$100
   GE Emphasizes on the Striking Features of New Vivid 7 Dimension ’06.....II-33
GE Launches Latest Innova Digital Flat Panel Biplane Imaging Devices.....II-33
Medtronic Introduces Latest Range of Implantable Cardiac Defibrillators.....II-33
Philips Introduces Web Based Cardiac Tools.....II-33
1$100
   Siemens Showcases Solutions for Cardiac Problems Through Molecular Imaging.....II-34
Siemens Presents Advancements in Echocardiography.....II-34
Siemens Debuts syngo BEAT.....II-34
Siemens Combines syngo® Dynamics with Soarian® for Cardiovascular EPR.....II-34
1$100
   GE Healthcare Unveils CardIQ Fusion.....II-35
GE Introduces VCT.....II-35
GE Unveils Dynamic VUE.....II-35
GE Launches CardIQ Xpress.....II-35
GE Presents the Ventri for Cardiac Imaging.....II-35
GE Introduces High Definition Magnetic Resonance System.....II-35
1$100
   Dade Behring Unveils CardioPhase(R) hsCRP Test.....II-36
Siemens Launches Encompass III on C512 Ultrasound Platform.....II-36
Siemens Launches Four New CT Clinical Engines.....II-36
Omron Launches HEM-9000AI Cardiovascular Diagnostic Tool.....II-36
Corgenix Introduces Predictive Cardiovascular Diagnostic Kit, AtherOx™.....II-36
1$100
   Philips Introduces HD11 XE Cardiology Ultrasound System.....II-37
Siemens Introduces Biplane FD Cardiology System.....II-37
Siemens Introduces Syngo Circulation Software for CT Tomography.....II-37
Siemens Introduces SOMATOM Definition for Cardiac Imaging.....II-37
Dade Behring Unveils Homocysteine Test on BN(TM) Systems.....II-37
1$100
   Roche Unveils Cardiac pro-BNP Test.....II-38
Philips Introduces HD11 XE.....II-38
Corgenix Unveils AtherOx(TM).....II-38
GE Healthcare Unveils Breakthrough Imaging Technology.....II-38
1$100
   Philips Launches Products to Detect Heart Problems.....II-39
Philips Unveils Computed Tomography and EP Planning package.....II-39
Philips Widens Magnetic Resonance Kitty.....II-39
New Cardiac Monitoring Products from Philips.....II-39
Siemens Launches Image-Arena.....II-39
1$100
   Siemens Announces New Procam-Calculator Combined with CT Examination.....II-40
Siemens Medical Solutions Launches Axiom Artis dTA.....II-40
GE Healthcare Unveils Vivid i.....II-40
1$100
   GE Healthcare Presents Fully Integrated 4D Cardiovascular Ultrasound System.....II-41
GE Healthcare Debuts New Imaging System.....II-41
New Discovery PET/CT Systems from GE Healthcare.....II-41
SonoSite Presents SonoCalc IMT Software.....II-41
1$100
   Dade Behring Introduces High Sensitivity Troponin I Assay.....II-42
Biosite Unveils New Diagnostic Test.....II-42
MDS Diagnostic Services Unveils New Test to Prevent Heart Disease.....II-42
1$100
   diaDexus Develops PLAC Test.....II-43
Siemens Introduces New Nuclear Cardiology Imaging System.....II-43
Roche Diagnostics Receives U.S. Clearance and European CE Mark.....II-43
Camtronics Unveils Cardiovascular Screening Software.....II-43
1$100
   Mayo Pioneers New Enzyme-Based Cardiovascular Risk Assessment Test.....II-44
1$100
  6. Recent Industry Activity.....II-4515 $800  
   Siemens Medical acquires Dade Behring.....II-45
Inverness Medical Innovations Acquires Cholestech.....II-45
Acrongenomics, Pearson and Molecular Enter into Joint Venture.....II-45
1$100
   Cholestech Teams Up with Onsite Health Diagnostics.....II-46
Lipomics to Collaborate with Agilent Technologies to Develop Diagnostic Tests......II-46
Transgenomic and Fiuotecnica Renew Collaboration Agreement.....II-46
Alteon and BioRap Technologies Enter into an Agreement.....II-46
1$100
   IM Medical Acquires New Technology for Detecting Cardiovascular Diseases.....II-47
Medtronic Establishes New Business Entity.....II-47
Siemens Medical Acquires Bayer Healthcare’s Diagnostics Unit.....II-47
Spacelabs Acquires Ferraris’ Cardiac Unit.....II-47
1$100
   Global Immune Takes over Primedical International.....II-48
Siemens Acquires Diagnostics Products.....II-48
Cholestech and Life Line Enter into Collaboration.....II-48
LipoScience Signs an Agreement with ARUP.....II-48
1$100
   Philips Acquires Witt Biomedical.....II-49
CardioDynamics Enters into an OEM Agreement with Shenzhen Mindray.....II-49
Biosense Enters into Strategic Partnership with Siemens Medical Solutions.....II-49
Dade Behring Approved the Use of FSAP Antibodies by American Diagnostica.....II-49
1$100
   Abbott Receives Non-exclusive Sublicense for Diagnostic Use of PIGF.....II-50
Nanogen Acquires Spectral’s Cardiac Test Division.....II-50
Varian Enters into Alliance with LipoScience to Jointly Develop NMR System.....II-50
Cardiac Services Professionals Establishes eCardio Diagnostics.....II-50
1$100
   Response Biomedical Wins Nonexclusive License Rights for NT-proBNP and Troponin
  T.....II-51
Biomerieux gains Nonexclusive License for NT-proBNP.....II-51
Philips and PMI Ink an Agreement for Outpatient Facility.....II-51
LipoScience Enters into an Agreement with LabCorp.....II-51
Abbott and Cleveland Clinic to Co-develop Myeloperoxidase Cardiac Test.....II-51
1$100
   Abbott Receives 510(k) Clearance from FDA for Myoglobin Test.....II-52
FDA Clears Additional Claim for Biosite’s Triage(R) BNP Test.....II-52
Biosite Inks an Agreement with University of Mainz.....II-52
Dade Behring Receives FDA Clearance for Advanced D-Dimer Assay.....II-52
Nanogen Acquires SYN•X Pharma.....II-52
GE Takes Over Amersham Plc.....II-52
1$100
   St. Jude Medical Acquires Irvine Biomedical and Epicor.....II-53
SonoSite Snaps Up SonoMetric.....II-53
CardioDynamics Purchases Vermed.....II-53
Philips and EP MedSystems Announce an Alliance Involving Electrophysiology
  Solutions.....II-53
Toshiba and ViTAL Enters into an Alliance with Johns Hopkins University School of
  Medicine.....II-53
Response Biomedical Collaborates with Shionogi.....II-53
1$100
   Terumo Signs Agreement with Spencer Technologies.....II-54
Spectral Diagnostics Announces Agreement with NGC Medical.....II-54
Philips Signs Agreement with Fletcher Allen Health Care.....II-54
Spectral Diagnostics Enters into an Agreement with Cardinal Health.....II-54
Siemens Signs Agreement with MediGuide.....II-54
1$100
   Biosite Enters into Agreement with DMI BioSciences.....II-55
Cambridge Heart Enters into Agreement with Del Mar Reynolds.....II-55
Cholestech Enters into an Agreement with Itamar Medical.....II-55
Siemens Enters into a Contract with HiPGraphics.....II-55
Abbott Announces US Clearance for Axis-Shield’s BNP Test for Use on AxSYM.....II-55
Cholestech Announces FDA 510(k) Approval for hs-CRP Test.....II-55
1$100
   Dade Behring Bags FDA Clearance NT-proBNP Test.....II-56
Dade Behring Receives FDA Clearance for N High Sensitivity CRP Assay.....II-56
EP-4 Computerized Cardiac Stimulator Bags FDA Approval.....II-56
Biosite Adds two new offices.....II-56
Bayer Diagnostics Enhances BNP Assay Offering Globally.....II-56
1$100
   EP MedSystems Garners CE Approval for ALERT Deflectable CS Catheter in Europe.....II-57
Cambridge Heart Inc and Quinton Cardiology Systems Renew Pact.....II-57
EPIX and Schering AG Extends Collaboration Agreement.....II-57
Siemens Ultrasound and TomTec Imaging Systems Announces Agreement.....II-57
1$100
   FIT Biotech Plc Acquires Xenerate Ab to Develop Innovative Cardiovascular
  Devices.....II-58
Beckman Coulter Enters into Agreement with Biosite.....II-58
Dade Behring Garners Non-exclusive Rights for a Key Cardiac Marker.....II-58
Bracco Diagnostics Inc., Joins Hand with Eastern Isotopes Inc to Develop
  CardioGen-82®.....II-58
1$100
   New Lab Test from diaDexus Receives FDA Clearance.....II-59
Hypertension Diagnostics Receives SDA Approval in China .....II-59
1$100
  7. Focus on Select Global Players.....II-604 $400  
   Abbott Diagnostics (USA) .....II-60
Biosite Inc. (USA).....II-60
Cambridge Heart, Inc. (USA).....II-60
1$100
   Cholestech Corp. (USA).....II-61
EP Medsystems (USA).....II-61
GE HealthCare (USA).....II-61
1$100
   Liposcience, Inc. (USA).....II-62
Philips Medical Systems (USA).....II-62
Roche Diagnostics (Switzerland).....II-62
1$100
   Siemens Medical Solutions (Germany).....II-63
1$100
  8. Global Market Perspective.....II-64   
   Table 1: World Recent Past, Current & Future Market Analysis for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-641$300
   Table 2: World Long-term Projections for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-651$300
   Table 3: World 10-Year Perspective for Cardiovascular Disease Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-661$300
   Table 4: World Recent Past, Current & Future Market Analysis for Cardiovascular In Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-671$300
   Table 5: World Long-term Projections for Cardiovascular In Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-681$300
   Table 6: World 10-Year Perspective for Cardiovascular In Vitro Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-691$300
   Table 7: World Recent Past, Current & Future Market Analysis for Cardiovascular In Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-701$300
   Table 8: World Long-term Projections for Cardiovascular In Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-711$300
   Table 9: World 10-Year Perspective for Cardiovascular In Vivo Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-721$300
III. MARKET78$1950
  1. The United States.....III-132 $1075  
   A. Market Analysis.....III-1
Startling Facts Related to Cardiovascular Disease in the US.....III-1
Cardio Vascular Disease (CVD) - An Overview.....III-1
1$75
   Table 10: Prevalence of Cardiovascular Disease in the US in the Recent Past (2004) (includes corresponding Graph/Chart).....III-2

Table 11: Percentage Breakdown of Deaths from Cardiovascular Diseases in the USin the Recent Past (2004) (includes corresponding Graph/Chart).....III-2
1$150
   Table 12: Prevalence of Cardiovascular Diseases among Americans by Age (Age 20 and Older) and Sex in the Recent Past (2004) (includes corresponding Graph/Chart).....III-3

Table 13: A Factoid of CHD and MI in the US in the Recent Past (2003) (In Million).....III-3
Startling facts related to Stroke in US.....III-3
1$150
   Table 14: A Factoid of Stroke in the US in the Recent Past (2003) (In Million).....III-4
Incidence of Coronary Heart Disease.....III-4
Mortality rate of CHD.....III-4
1$150
   Table 15: Annual Number of Americans Having Diagnosed Heart Attack by Age and Sex in the Recent Past (2004) (includes corresponding Graph/Chart).....III-5

Table 16: Prevalence of CHD by Age and Sex in the Recent Past (2004) (In % population) (includes corresponding Graph/Chart).....III-5
Arrhythmias.....III-5
1$150
   CAD Diagnostics.....III-6
PVD Diagnostics.....III-6
Medicare Reimbursement Set for CPT Code 83704.....III-6
Competitive Glance.....III-6
Point-of-Care (POC) Diagnostic Market in the US.....III-6
1$75
   Table 17: Leading Players in the US POC Cardiac Market (2004) - Percentage Breakdown by Value Sales for Biosite, Dade Behring, Spectral Diagnostics, Roche and Others (includes corresponding Graph/Chart).....III-7
Review of Major Players.....III-7
Abbott Diagnostics .....III-7
Biosite Inc.....III-7
1$150
   Cambridge Heart, Inc.....III-8
Cholestech Corp.....III-8
1$75
   EP Medsystems.....III-9
Liposcience, Inc......III-9
Philips Medical Systems.....III-9
1$75
   Product Launches/Developments.....III-1011$275
   Strategic Developments.....III-2110$250
   B. Market Analytics.....III-31
Table 18: US Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-31
1$150
   Table 19: US Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-32

Table 20: US 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-32
1$150
  2. Canada.....III-334 $275  
   A. Market Analysis.....III-33
Product Launch.....III-33
Strategic Developments.....III-33
2$100
   B. Market Analytics.....III-35
Table 21: Canadian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-35

Table 22: Canadian Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-35
1$150
   Table 23: Canadian 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-36
1$150
  3. Japan.....III-372 $200  
   A. Market Analysis.....III-37
Strategic Developments.....III-37
B. Market Analytics.....III-37
Table 24: Japanese Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-37
1$150
   Table 25: Japanese Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-38

Table 26: Japanese 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-38
1$150
  4. Europe.....III-397 $525  
   A. Market Analysis.....III-39
European Union Cardiovascular Diseases Fact Sheet.....III-39
In Vivo Diagnostics - Leading Segment.....III-39
Germany - The Largest European Market.....III-39
1$75
   Product Launches.....III-402$100
   B. Market Analytics.....III-42
Table 27: European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-42
1$150
   Table 28: European Long-term Projections for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-43

Table 29: European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-43
1$150
   Table 30: European Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-44

Table 31: European 10-Year Perspective for Cardiovascular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-44
1$150
   Table 32: European 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-45
1$150
  4a. France.....III-462 $175  
   A. Market Analysis.....III-46
Strategic Development.....III-46
B. Market Analytics.....III-46
Table 33: French Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-46
1$150
   Table 34: French Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-47

Table 35: French 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-47
1$150
  4b. Germany.....III-487 $350  
   A. Market Analysis.....III-48
Siemens Medical Solutions - A Major Player.....III-48
Product Launches.....III-48
4$150
   Strategic Developments.....III-521$75
   B. Market Analytics.....III-53
Table 36: German Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-53

Table 37: German Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-53
1$150
   Table 38: German 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-54
1$150
  4c. Italy.....III-553 $225  
   A. Market Analysis.....III-55
Strategic Developments......III-55
1$75
   B. Market Analytics.....III-56
Table 39: Italian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-56

Table 40: Italian Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-56
1$150
   Table 41: Italian 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-57
1$150
  4d. The United Kingdom.....III-583 $275  
   A. Market Analysis.....III-58
UK Cardiovascular Diseases Fact Sheet.....III-58
1$75
   Key Player Review .....III-59
GE HealthCare .....III-59
B. Market Analytics.....III-59
Table 42: UK Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-59
1$150
   Table 43: UK Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-60

Table 44: UK 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-60
1$150
  4e. Spain.....III-612 $175  
   Market Analysis.....III-61
Table 45: Spanish Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-61
1$150
   Table 46: Spanish Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-62

Table 47: Spanish 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-62
1$150
  4f. Russia.....III-632 $175  
   Market Analysis.....III-63
Table 48: Russian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-63
1$150
   Table 49: Russian Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-64

Table 50: Russian 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-64
1$150
  4g. Rest of Europe.....III-653 $225  
   A. Market Analysis.....III-65
Roche Diagnostics - A Key Swiss Player.....III-65
1$75
   B. Market Analytics.....III-66
Table 51: Rest of Europe Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-66

Table 52: Rest of Europe Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-66
1$150
   Table 53: Rest of Europe 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-67
1$150
  5. Asia Pacific.....III-686 $475  
   A. Market Analysis.....III-68
Cardiovascular Market in Asia-Pacific.....III-68
China.....III-68
Cardiovascular Disease Patients Overview.....III-68
1$75
   Treatment Providers and Hospitals Overview.....III-69
Hospitals.....III-69
Table 54: Cardiovascular Special Treatment Hospitals in China: 1991-2011(In numbers) (includes corresponding Graph/Chart).....III-69
Chinese Cardiovascular Disease Treatment as a Part of Overall Health Care
  Industry.....III-69
1$150
   Table 55: Cardiovascular Diseases Treatment inChina: 1991-2011(In US$ million) (includes corresponding Graph/Chart).....III-70
Strategic Developments.....III-70
2$200
   B. Market Analytics.....III-72
Table 56: Asia-Pacific Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-72

Table 57: Asia-Pacific Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-72
1$150
   Table 58: Asia-Pacific 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-73
1$150
  6. The Middle East.....III-742 $175  
   Market Analysis.....III-74
Table 59: Middle East Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-74
1$150
   Table 60: Middle East Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-75

Table 61: Middle East 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-75
1$150
  7. Latin America.....III-763 $375  
   A. Market Analysis.....III-76
Strategic Development.....III-76
1$75
   B. Market Analytics.....III-77
Table 62: Latin American Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-77

Table 63: Middle East Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-77
1$150
   Table 64: Latin American 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010.....III-781$150
IV. COMPETITIVE LANDSCAPE248$995
  
Total Companies Profiled: 72 (including Divisions/Subsidiaries - 84)

Region/Country                 Players

The United States                  58
Canada                              3
Japan                               4
Europe                             14
     France                         1
     Germany                        1
     The United Kingdom             5
     Italy                          3
     Rest of Europe                 4
Asia-Pacific (Excluding Japan)      3
Middle East                         2
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2009, Global Industry Analysts, Inc., USA.